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Discs large homolog 5 (Dlg5) is a member of the membrane-associated guanylate kinase adaptor
family of proteins and is involved in epithelial-to-mesenchymal transition via transforming growth
factor-b (TGF-b) signaling. However, the mechanism underlying the regulation of TGF-b signaling is
unclear. We show here that Dlg5 interacts and colocalizes with both TGF-b type I (TbRI) and type II
(TbRII) receptors at the plasma membrane. TbRI activation is not required for this interaction. Fur-
thermore, the overexpression of Dlg5 enhances the degradation of TbRI. Proteasome inhibitors
inhibited this enhanced degradation. These results suggest that Dlg5 interacts with TbRs and pro-
motes their degradation.
Structured summary of protein interactions:
DLG5 physically interacts with TbRII and TbRI by anti tag coimmunoprecipitation (View interaction)
DLG5 physically interacts with TbRII by anti tag coimmunoprecipitation (View interaction)
TbRI physically interacts with DLG5 by anti bait coimmunoprecipitation (View interaction)
DLG5, TbRI and TbRII colocalize by ﬂuorescence microscopy (View interaction)
DLG5 physically interacts with TbRI by anti tag coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction disease (CD), which is an inﬂammatory bowel disease (IBD)Discs large homolog 5 (Dlg5) is a member of the membrane-
associated guanylate kinase (MAGUK) adaptor family of proteins.
Each MAGUK family member has at least one PDZ (PSD-95, Dlg,
ZO-1) domain, an SH3 (Src homology 3) domain, and a guanylate
kinase domain. Dlg5 was initially proposed to be one of ﬁve human
homologs of the Drosophila discs large (Dlg) protein, a tumor sup-
pressor gene which is required for tumor suppression in imaginal
discs, based on similarities in their sequences and domain struc-
tures [1,2]. However, Dlg5 has its own ortholog in other animals
including Drosophila, thus it does not belong to the DLG MAGUK
subfamily but seems to have its own function [2]. We have identi-
ﬁed Dlg5 as a binding protein for vinexin [3,4] and shown that Dlg5
associates with b-catenin and that it localizes at cell–cell adhesion
sites. Several other Dlg5 binding proteins, including p55 [1], syn-
taxin 4 [5] and citron kinase [6], have been identiﬁed. It has been
reported that Dlg5 polymorphisms are associated with Crohn’s[7–11]. Dlg5 knockout mice showed defects in the kidney and brain
[5] as well as abnormal cell polarity. However, these phenotypes
cannot explain the pathogenesis of CD.
Recently, we showed that Dlg5 suppresses the epithelial-
to-mesenchymal transition (EMT) of renal epithelial cells via the
inhibition of TGF-b receptor-dependent signaling [12]. TGF-b stim-
ulation induces intracellular signals via two serine-threonine ki-
nase receptors, type I (TbRI) and type II (TbRII) TGF-b receptors.
Both TbRI and TbRII form stable homodimers in the absence of
TGF-b. Upon TGF-b binding, TbRI homodimers and TbRII homodi-
mers form a heterotetrameric receptor complex, leading to the
activation of two downstream signaling pathways [13–15]. The
ﬁrst pathway is Smad signal, in which TGF-b stimulation results
in TbRI-mediated phosphorylation of receptor-regulated Smads
(Smad2 and Smad3). Phosphorylated Smad2 and Smad3 bind to
the common mediator Smad (Smad4). The Smad2/3/4 complexes
then accumulate in the nucleus and regulate target gene transcrip-
tion. The other pathway is non-Smad signal. TbRI activates c-Jun
N-terminal kinases (JNK) and p38 mitogen-activated protein
kinases (p38 MAPK) through MKK4 and MKK3/6, respectively,
independent of Smad signals. Dlg5 depletion in LLc-PK1 renal prox-
imal tubule epithelial cells increases the activation of JNK and p38
MAPK, which are necessary to induce the EMT of these cells [12].
Dlg5 seems to affect TbR because speciﬁc inhibition of TbRI or
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dent signaling, suppresses Dlg5 depletion-induced EMT. However,
the mechanism by which Dlg5 regulates TbR is unknown. Here, we
show that Dlg5 interacts with TbRI and enhances its degradation.
2. Materials and methods
2.1. Antibodies and reagents
MG132 and N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN)
were purchased from Calbiochem. Baﬁlomycin and cycloheximide
were from WAKO Pure Chemical Industries, Osaka, Japan and Sig-
ma, respectively. The following antibodies were used in this study:
anti-Flag (Sigma), anti-GFP (WAKO Pure Chemical Industries), anti-
GFP (Santa Cruz Biotechnology), anti-TbRI (Santa Cruz Biotechnol-
ogy), anti-b-tubulin (Sigma), and anti-vinculin (Sigma) antibodies.
The anti-Dlg5 antibody was described previously in [3].
2.2. Cell culture, plasmids, and transfection
The 293T and Caco-2 cells (RIKEN BRC through the National Bio-
Resource Project of the MEXT, Japan) were maintained in Dul-
becco’s Modiﬁed Eagle Medium containing 10% fetal bovine serum.
PC3 cells (obtained from Dr. Yoshiyuki Kakehi of Kagawa Univer-
sity) were maintained in RPMI-1640 medium containing 10% fetal
bovine serum. The longest variant of Dlg5 (Dlg5a, see Fig. 1E),
which includes 1919 amino acids containing CARD (caspaseFig. 1. GFP-Dlg5 is coimmunoprecipitated with TbRI-Flag and TbRII-HA. (A–C) GFP or G
HA-tagged TbRII (A), Flag-tagged TbRI (B) or HA-tagged TbRII (C). Cell lysates were subje
examined using the antibodies indicated. Arrows mean differentially glycosylated forms o
was transfected into 293T cells. Cell lysates were immunoprecipitated with anti-GFP
Schematic diagram showing the protein domains of Dlg5a, -b, and -DCC. Dlg5a contains
are splice variants. Dlg5DCC is a deletion mutant that lacks the CARD and coiled-coil dorecruitment domain), coiled-coil, SH3, and GUK domains, as well
as four PDZ domains, was purchased from Promega (Madison,
USA). A shorter variant (Dlg5b), which lacks the CARD domain,
was described previously in [3]. Dlg5DCC, which lacks the CARD
and coiled-coil domains and corresponds to an open reading frame
of KIAA0583 (AB011155), was obtained from the Kazusa DNA
Research Institute. Plasmids encoding the TGF-b receptors (TbRI-
FLAG and TbRII-HA, both of which are epitope-tagged at C-termi-
nus) were gifts from Dr. S. Aota (RIKEN, Japan). Transfection of
plasmid DNA was performed using Lipofectamine LTX (Invitrogen)
according to the manufacturer’s instructions.
2.3. RNA interference (RNAi)
The stealth siRNAs for Dlg5/lp-dlg (GGAUUCCAUGGAGUGG-
GAAACGGAA) were designed based on the sequence of the human
Dlg5 cDNA (NP_004738) and synthesized by Invitrogen. The trans-
fection of siRNAs (10 nM) was performed using Lipofectamine
RNAiMAX (Invitrogen) as previously described in [16].
2.4. Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as
previously described in [12,17]. Brieﬂy, cells cultured under vari-
ous conditions were washed with PBS. The cells were then lysed
in RIPA buffer without SDS (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 50 mM Tris–HCl pH 7.5, 0.1 mg/ml p-amidinophenylFP-Dlg5DCC were cotransfected into 293T cells together with Flag-tagged TbRI and
ct to immunoprecipitation (IP) with an anti-GFP antibody. Immune complexes were
f TbRII. (D) TbRI-Flag, as well as either GFP, GFP-Dlg5a, GFP-Dlg5b or GFP-Dlg5DCC,
antibody, and immunoblotting was performed with the antibodies indicated. (E)
CARD, coiled-coil, SH3, and GUK domains, as well as four PDZ domains. Dlg5a and b
mains.
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nin) on ice for 30 min. Lysates were centrifuged at 18700g for
10 min. For immunoprecipitation, equal amounts of cell lysate
were incubated with the indicated antibodies for 1 h and then with
Protein G Sepharose beads for 1 h. For immunoblotting, cell lysates
or immunoprecipitates were electrophoresed and transferred onto
PVDF membranes (Millipore). After blocking with BLOCKING ONE
(Nacalai Tesque, Kyoto, Japan), the membranes were incubated
with primary antibodies and then with the appropriate secondary
antibodies. Antigen detection was performed with an LAS 3000 im-
age analyzer (FUJIFILM, Tokyo, Japan) using the ImmunoStar LD kit
(Wako, Osaka, Japan). Quantiﬁcation was performed by Multi
Gauge (FUJIFILM, Tokyo, Japan).Fig. 2. Endogenous Dlg5 is coimmunoprecipitated with TbRI in PC3 cells. PC3 cells
were transfected with Dlg5 siRNA and incubated for 3 days. The cells were then
lysed and immunoprecipitated with anti-TbRI antibody or control IgG. The immune
complexes were examined with the antibodies indicated.2.5. Immunostaining
Caco-2 cells were transfected with plasmids encoding GFP-
Dlg5DCC, TbRI-Flag and TbRII-HA. The cells were cultured on cov-
erslips coated with type IV collagen for 24 h. Cells were ﬁxed with
methanol for 20 min at 20 C and blocked with 10% goat serum in
PBS+ for 30 min. They were then incubated with anti-Flag antibody
and anti-HA antibody for 1 h at room temperature, followed by
incubation with Alexa 633-labeled goat anti-rabbit IgG (Invitro-
gen) and Alexa 546-labeled goat anti-rat IgG for 1 h. Fluorescence
imaging was performed with a LSM700 confocal microscopy sys-
tem (Carl Zeiss Co., Ltd.).
2.6. Statistical analysis
The statistical analysis was performed using Student’s paired t-
test.Fig. 3. TbRI activation and kinase activity are not necessary for binding to Dlg5. (A)
GFP-Dlg5DCC, together with Flag-tagged wild type (WT), constitutively active (CA)
or kinase-dead (KD) TbRI, was transfected into 293T cells. Cell lysates were
immunoprecipitated (IP) with anti-GFP antibody and immunoblotted with the
antibodies indicated. The expression levels of KD-TbRI were low for unknown
reasons. (B) 293T cells were transfected with Flag-tagged TbRI and GFP-tagged
Dlg5DCC. The cells were then treated with TGF-b for 30 or 180 min, followed by
immunoprecipitation and immunoblotting with the antibodies indicated. (C) PC3
cells were treated with or without TGF-b for 30 min, followed by immunoprecip-
itation and immunoblotting with the antibodies indicated.3. Results
3.1. Dlg5 interacts with TbRI and TbRII
Previously, we showed that Dlg5 suppresses EMT through the
inhibition of TGF-b receptor-mediated signaling [12]. Several mol-
ecules, including Smad7 and Smurf1/2, attenuate TGF-b signaling
via binding to the TbRs [18]. To examine whether Dlg5 can interact
with TbRs, TbRI-Flag and TbRII-HA were cotransfected with GFP-
tagged Dlg5 variant (GFP-Dlg5DCC) into 293T cells, followed by
coimmunoprecipitation using an anti-GFP antibody. As shown in
Fig. 1A, both TbRI and TbRII were coprecipitated with Dlg5DCC.
To check whether Dlg5 could bind TbRI independent of TbRII and
vice versa, we performed immunoprecipitation assays. GFP-
Dlg5DCC was transfected into 293T cells with TbRI-Flag and then
immunoprecipitated with anti-GFP antibody. TbRI (Fig. 1B) was
coprecipitated with Dlg5DCC. The reciprocal coimmunoprecipita-
tion experiment conﬁrmed this interaction (data not shown). We
also examined whether the interaction of Dlg5 with TbRII depends
on TbRI. GFP-Dlg5DCC was transfected into 293T cells with TbRII-
HA and then immunoprecipitated with anti-GFP antibody. TbRII
(Fig. 1C) was coprecipitated with Dlg5DCC. These results indicate
that Dlg5 can interact with both TbRI and TbRII independently.
Dlg5 has splice variants, such as Dlg5a and b (Fig. 1E, also see Sec-
tion 2). To determine which Dlg5 splice variants can interact with
the TbRs, coimmunoprecipitation experiments with Dlg5a, -b, and
-DCC were performed. TbRI coprecipitated with all these Dlg5 vari-
ants (Fig. 1D), suggesting that these variants all contain the TbRI
interaction region. Because TbRI coprecipitated the most effec-
tively with Dlg5DCC, possibly because Dlg5a and Dlg5b were less
soluble in the lysis buffer than Dlg5DCC (Fig. 1D), primarily
Dlg5DCC was used in subsequent experiments.To conﬁrm the interaction between endogenous Dlg5 and the
TbRs, we performed coimmunoprecipitation experiments using
PC3 prostate cancer cells in which Dlg5 is expressed at high levels.
The PC3 cell lysates were subject to immunoprecipitation with
anti-TbRI antibody and examined for coimmunoprecipitation of
endogenous Dlg5. As shown in Fig. 2, Dlg5 was detected when
anti-TbRI antibody, but not control IgG, was used for the immuno-
precipitation. Transfection of Dlg5 siRNA reduced the expression of
Dlg5 in lysates as well as in the coprecipitation of Dlg5 with TbRI.
We could not detect coimmunoprecipitation of endogenous TbRII
with Dlg5 because it could not be immunoprecipitated efﬁciently
(data not shown). These results suggest that Dlg5 binds TbRI under
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experiments.
3.2. TbRI activation and kinase activity are not necessary for Dlg5
binding
The interactions of TbRI with Smad7, SARA (Smad anchor for
receptor activation), and TAK1 (TGF-b activated kinase 1) are regu-
lated byTbRI activation [18–21]. To investigatewhether TbRI activa-
tion affects its interaction with Dlg5, coimmunoprecipitation
experiments using constitutively active (CA-TbRI T204D) and ki-
nase-dead (KD-TbRI D351A) TbRI mutants were performed. As
shown in Fig. 3A, CA-TbRI and KD-TbRI were coimmunoprecipitated
withDlg5 similarly toWT-TbRI.Next,weexamined theeffect of TGF-
b stimulation on the Dlg5–TbRI interaction. After cotransfection of
TbRI with GFP-Dlg5DCC, the cells were incubated with TGF-b for
30 or 180 min before immunoprecipitation was performed
(Fig. 3B). TbRIwas coimmunoprecipitatedwithGFP-Dlg5DCCbefore
TGF-b stimulation. Thirty minutes after TGF-b stimulation, phos-
phorylated Smad2 was detected, thus indicating the activation of
TbRI.However, the amountof TbRI coimmunoprecipitatedwas com-
parable to that before TGF-b stimulation, even after TGF-b stimula-
tion for 30 or 180 min (Fig. 3B). We also examined the effect of
TGF-b stimulation on the interaction of endogenous proteins. PC3
cells were treated with or without TGF-b, then cell lysates were
immunoprecipitated with anti-TbRI antibody. Coimmunoprecipi-
tated Dlg5 with TbRI in TGF-b treated cells was comparable to that
in untreated cells (Fig. 3C). These results suggest that TbRI activation
and kinase activity are not necessary for binding to Dlg5.
3.3. Dlg5 colocalizes with TbRs at the plasma membrane
To test for colocalization of Dlg5 with the TbRs in cells, Caco-2
colon epithelial cells were used. Caco-2 cells have well-organizedFig. 4. Dlg5 colocalizes with TbRI and TbRII. Caco-2 cells were cotransfected with TbRI-F
Flag and anti-HA antibodies. Dlg5 was visualized by GFP ﬂuorescence.cell–cell adhesion structures where Dlg5 localizes (data not
shown). GFP-Dlg5DCC, TbRI-Flag, and TbRII-HA were cotransfected
into Caco-2 cells. Cells were ﬁxed and immunostained with anti-
Flag and anti-HA antibodies. GFP-Dlg5DCC localized to the plasma
membrane as well as diffusely (Fig. 4), which is consistent with a
previous report [3]. Both TbRI-Flag and TbRII-HA were also de-
tected at the plasma membrane as well as in the cytosol (Fig. 4).
The merged image indicates the colocalization of TbRI, TbRII, and
GFP-Dlg5DCC at the plasma membrane. These results suggest that
GFP-Dlg5DCC, TbRI-Flag, and TbRII-HA colocalize at the plasma
membrane in Caco-2 cells.
3.4. Dlg5 overexpression promotes TbRI degradation
The degradation of TbRI and TbRII is one of main regulatory
mechanisms of TGF-b signaling [18,22–25]. To investigate whether
Dlg5 affects TbRI degradation, GFP-Dlg5DCC and TbRI-Flag were
cotransfected into 293T cells. Twenty-four hours after transfection,
cycloheximide was added to the culture medium to inhibit protein
synthesis. After further incubation for 0–8 h, TbRI expression was
examined by immunoblotting with anti-Flag antibody. As shown
in Fig. 5A, TbRI levels decreased only slightly over time in control
cells. In contrast, TbRI levels decreased signiﬁcantly faster in
Dlg5DCC-expressing cells. A quantitative analysis showed that
the amount of TbRI was reduced to 80% and 50% in control and
Dlg5DCC-expressing cells, respectively, 4 h after the addition of
cycloheximide (Fig. 5B). Consistent with this overexpression
experiments, Dlg5 knockdown in PC3 cells signiﬁcantly increased
the TbRI expression both under TGF-b, -stimulated and -unstimu-
lated conditions (Fig. 5C and D). TbRII degradation after cyclohex-
imide treatment was also examined in 293T cells, but it was very
slow and no decrease in TbRII protein levels was detected, even
8 h after cycloheximide treatment (data not shown). These results
suggest that Dlg5 promotes the degradation of TbRI.lag, TbRII-HA and GFP-Dlg5DCC. The cells were ﬁxed and immunostained with anti-
Fig. 5. Dlg5 promotes TbRI degradation. (A) GFP-Dlg5DCC and TbRI-Flag were cotransfected into 293T cells. Twenty-four hours after transfection, 100 lg/ml cycloheximide
was added to the culture medium to inhibit protein synthesis. After further incubation for 0–8 h, TbRI expression was determined by immunoblotting with an anti-Flag
antibody. (B) The relative TbRI expression in A was quantiﬁed. The values represent the mean ± S.E. from three independent experiments. (C) PC3 cells were transfected with
Dlg5 siRNA and incubated for 3 days. The cells were then treated with TGF-b for 30 min, followed by immunoblotting with the indicated antibodies. Vinculin was used as a
loading control. (D) TbRI expression in C was quantiﬁed. The values represent the mean ± S.E. from three independent experiments.
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degradation, which is enhanced by its interaction with Smad7
[18,24]. To test which degradation pathway is engaged by Dlg5,
cells were cotransfected with GFP-Dlg5DCC and TbRI-Flag and then
treated with the proteasome inhibitor MG132 or the lysosome
inhibitor baﬁlomycin for 8 h. Consistent with Fig. 5, Dlg5DCC over-
expression signiﬁcantly decreased TbRI protein levels (Fig. 6A and
D). Treatment with MG132 signiﬁcantly increased TbRI levels inFig. 6. Dlg5-enhanced TbRI degradation involves proteasome. (A–C) Cells were cotransfec
baﬁlomycin (C). After incubation for 8 h, TbRI levels were determined by immunoblottin
expression in A–C was quantiﬁed. The values represent the mean ± S.E. from three indeDlg5DCC-overexpressing cells but not in control cells (Fig. 6B and
E). Quantitative analysis showed that MG132 treatment increased
TbRI levels 1.3-fold. Another proteasome inhibitor, ALLN, also in-
creased TbRI levels in GFP-Dlg5DCC expressing cells (data not
shown). In contrast, baﬁlomycin increased TbRI levels in both con-
trol and Dlg5DCC-overexpressing cells (Fig. 6C and F). These re-
sults suggest that Dlg5 enhances the proteasome-dependent
degradation of TbRI.ted with GFP-Dlg5DCC and TbRI-Flag, then treated without (A) or with MG132 (B) or
g with the antibodies indicated. Vinculin was used as a loading control. (D–F) TbRI
pendent experiments.
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Dlg5, a member of the MAGUK family of adaptor proteins, local-
izes at cell–cell adhesion sites. We previously showed that Dlg5
suppresses TbR-mediated signaling and EMT in renal epithelial
cells [12]. However, the mechanism of this suppression is un-
known. In this research, we found that both TbRI-Flag and TbRII-
HA were clearly coprecipitated with Dlg5DCC. Furthermore,
endogenous Dlg5 was also coimmunoprecipitated with endoge-
nous TbRI in PC3 cells. GFP-Dlg5 was colocalized with TbRI-Flag
and TbRII-HA at cell–cell adhesion sites in Caco-2 cells. These re-
sults indicate that Dlg5 forms a signaling complex with TbRs at
the plasma membrane.
We showed here that treatment with proteasome inhibitors
suppressed Dlg5DCC-enhanced TbRI degradation. Lysosome inhib-
itor increased the TbRI expression in Dlg5DCC-expressing cells but
it also increased the expression in control cells, implying that Dlg5
enhanced TbRI degradation via proteasome-dependent mecha-
nisms. In some cases, negative regulators of TGF-b signaling
associate with TbRs and promote TbR degradation via proteasome-
and lysosome-dependent pathways simultaneously [18,24,25]. In
other cases, only proteasomal degradation contributes to the TbR
degradation [26]. Cellular context may explain the different path-
way for the TbRI degradation.
Expression of the TGF-b -signaling inhibitor Smad7 is enhanced
by TGF-b stimulation itself. The interaction of TbRI with Smad7 is
stimulated by TbRI activation [18–20]. Thus, Smad7 seems to func-
tion in a negative feedback loop regulating TGF-b signaling. In con-
trast, the interaction of Dlg5 with TbRI was not stimulated by TbRI
activation. Both the constitutively active mutant of TbRI (CA-TbRI)
and the kinase-dead mutant KD-TbRI bind Dlg5 in a manner com-
parable to the wild type receptor. TGF-b stimulation for 30 or
180 min did not affect these interactions. Furthermore, Dlg5
expression decreases after TGF-b stimulation [12]. Thus, Dlg5
seems to participate in positive feedback (speciﬁcally double-neg-
ative type feedback [27,28]) loop regulating TGF-b signaling but
not in a normal negative feedback loop. Alternatively, Dlg5 may
suppress leaky (non-speciﬁc) activation of TGF-b signaling by bind-
ing TbRs, in a mechanism similar to FKBP12 [29].
The dysregulation of TGF-b signaling increases the risk of CD.
TGF-b 1 knockout mice develop systemic inﬂammation, including
in the gut [30]. High levels of Smad7 are observed in CD patients
[31], and its knockdown attenuates experimental colitis in mice
[32]. We found that Dlg5 interacts with TbRs and promotes their
degradation. These results may explain how Dlg5 polymorphisms
affect the development of IBD, including CD. Future experiments
will be directed towards understanding the relationship between
Dlg5 polymorphisms and the regulation of TbR signaling.
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